PROMOTING ACCESS TO AFRICAN RESEARCH

Tropical Journal of Obstetrics and Gynaecology

Log in or Register to get access to full text downloads.

Remember me or Register



Cervical Cancer Vaccination

AR Ajiboye

Abstract


Background: In 2006, the world’s first cervical cancer vaccine became available for public use. Two human papilloma virus (HPV) vaccines, Gardasil & Cervarix were licensed, both protecting against the most common cancer-causing HPV types (HPV 16 and 18), and Cervarix also
protecting against genital warts (including in addition, types 6 and 11). A good understanding of the vaccine, its role in the primary prevention of cervical cancer and pre cancers is vital in reducing the high morbidity and mortality associated with cervical cancer.
Objective: This article provides an overview of cervical cancer vaccine including safety, efficacy and cost in the primary prevention of cervical cancer.
Discussion: The quadrivalent human papilloma virus (HPV) vaccine protects against HPV types 6, 11, 16 and 18. These HPV types are responsible for 70% of cervical cancers, 90% of genital warts and a substantial proportion of cervical abnormalities. The quadrivalent human
papilloma virus (HPV) vaccine is indicated for females aged 9 -26 years and males aged 9-15 years and should ideally be administered before the onset of sexual activity, however, sexually active patients will also benefit. These vaccines are expected to be able to prevent about 70% of
cervical cancer cases worldwide



AJOL African Journals Online